SCHEMBL29455091

CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)[C@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 13)

	gene	UniProt	supporting neighbours	confidence
▸	KISS1R	Q969F8	3/20	0.59

▸	NTSR2	O95665	1/20	0.59

▸	NTSR1	P30989	1/20	0.59

▸	NMBR	P28336	2/20	0.58

▸	GRPR	P30550	2/20	0.58

▸	GNRHR	P30968	2/20	0.58

▸	F2	P00734	4/20	0.58

▸	ABCC2	Q92887	1/20	0.58

▸	NPY1R	P25929	4/20	0.58

▸	NPY2R	P49146	2/20	0.58

▸	NPY4R	P50391	2/20	0.58

▸	NPY5R	Q15761	2/20	0.58

▸	PTGS1	P23219	1/20	0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29376164	0.85	GNRHR (0.68)	KISS1RNMBRGRPRGNRHRF2
SCHEMBL30186660	0.84	GNRHR (0.67)	KISS1RNMBRGRPRGNRHRF2
SCHEMBL29598775	0.83	NMBR (0.62)	KISS1RNMBRGRPRNPY1RNPY2R
SCHEMBL29491173	0.82	C5AR1 (0.65)	KISS1RNMBRGRPRGNRHRF2
Dynorphin A (1-17) SCHEMBL29599476	0.82	OPRD1 (0.70)	NTSR2NTSR1NMBRGRPRF2
SCHEMBL30906422	0.82	NPY1R (0.68)	NPY1RNPY2RNPY4RNPY5R
SCHEMBL29466602	0.82	NMBR (0.62)	NMBRGRPRGNRHRF2ABCC2
SCHEMBL31073551	0.82	NPY1R (0.69)	NPY1RNPY2RNPY4RNPY5R
SCHEMBL31182478	0.82	NPY1R (0.67)	NPY1RNPY2RNPY4RNPY5R
SCHEMBL30906380	0.81	NPY1R (0.68)	NPY1RNPY2RNPY4RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
WO-2024051817-A1	TUMOR-TARGETED FUSION PROTEIN TYPE MEDICAMENT PRECURSOR TAKING INTERLEUKIN 2 AS ACTIVE INGREDIENT	北京昌平实验室	2024-03-14	—	—	WO	claimed
US-12448425-B2	Therapeutic peptides	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US)	2025-10-21	—	—	US	disclosed
US-20240374705-A1	MUCOADHESIVE-PLGA NANOPARTICLES	PRESTIGE BIOPHARMA IDC CO., LTD (KR)	2024-11-14	—	—	US	disclosed
US-20240125764-A1	COMPOSITIONS AND METHODS FOR TEMPORAL CONTROL OF CELL MODULATION	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	2024-04-18	—	—	US	disclosed
WO-2024051817-A1	TUMOR-TARGETED FUSION PROTEIN TYPE MEDICAMENT PRECURSOR TAKING INTERLEUKIN 2 AS ACTIVE INGREDIENT	北京昌平实验室	2024-03-14	—	—	WO	disclosed
CN-117683140-A	Tumor-targeted fusion protein type prodrug taking interleukin 2 as active ingredient	北京昌平实验室	2024-03-12	—	—	CN	disclosed
WO-2024025059-A1	MUCOADHESIVE-PLGA NANOPARTICLES	프레스티지바이오파마코리아 주식회사	2024-02-01	—	—	WO	disclosed
US-20220213165-A1	THERAPEUTIC PEPTIDES	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US)	2022-07-07	—	—	US	disclosed
EP-3966567-A1	THERAPEUTIC PEPTIDES	Board of Regents, The University of Texas System (US)	2022-03-16	—	—	EP	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20240374705-A1	MUCOADHESIVE-PLGA NANOPARTICLES	MUC1, CD81, EPCAM	KISS1R 310/4885NTSR2 2468/4885NTSR1 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.